Objective: To investigate the differential expression of miR-126-5p in patients with lung adenocarcinoma and explore the possible mechanism.
Methods: We searched STARBASE database to analyze the differential expression of miR-126-5p between lung adenocarcinoma tissues and normal lung tissues. The prognosis of patients with lung adenocarcinoma was analyzed on Kaplan-Meier Plotter online website, and the survival curves of the patients with different expression levels of miR-126-5p were generated. The target gene of mir-126-5p was predicted by STARBASE database, and the expression level of the target gene and its influence on the patients' prognosis were analyzed using online website tool. We also examined the expression levels of miR-126-5p in peripheral serum of 30 healthy control subjects and 30 patients with lung adenocarcinoma using qPCR.
Results: Analysis of the data from STARBASE database showed a high expression of miR-126-5p in normal lung tissues but a low expression in lung adenocarcinoma tissues. Kaplan-Meier Plotter online analysis based on big data analysis showed that patients with a high expression of miR-126-5p had a better survival prognosis than those with a low expression (HR=0.68, P=0.015). MiR-126-5p was predicted to bind to the 3'UTR region of BRCC3 mRNA, and their expression levels were negatively correlated (r=0.197, P < 0.05). Compared with normal tissues, lung adenocarcinoma tissues expressed high levels of BRCC3, which was associated with a poor prognosis of the patients (HR=1.39, P < 0.05). The serum level of miR-126-5p was significantly higher in healthy control subjects than in patients with lung adenocarcinoma (1.23 ± 0.21 vs 0.63 ± 0.12, P < 0.05).
Conclusions: The expression level of miR-126-5p is lowered in lung adenocarcinoma tissue, and patients with lung adenocarcinoma have lower serum level of miR-126-5p than healthy subjects. A high expression of miR-126-5p is associated with a more favorable prognosis of the patients than a low expression. miR-126-5p may play a role against cancer by regulating BRCC3.
目的: 探讨肺腺癌患者miR-126-5p的表达差异性及其在患者临床预后中的价值, 基于生物信息学方法, 分析其作用机制。
方法: 检索STARBASE数据库, 分析肺腺癌组织和正常肺组织中miR-126-5p表达水平差异。使用Kaplan-Meier Plotter在线网站分析肺腺癌患者生存预后, 绘制癌组织miR-126-5p不同表达水平患者的生存曲线。利用STARBASE数据库预测miR-126-5p作用的靶基因, 在线网站分析靶基因的表达水平及对预后的影响。使用qPCR法检测30例健康对照组及30例肺腺癌患者外周血清mir-126-5p表达水平。
结果: STARBASE数据库检索结果提示正常肺组织中miR-126-5p高表达, 肺腺癌组织中miR-126-5p低表达, Kaplan-Meier Plotter在线大数据分析提示肺腺癌组织中miR-126-5p高表达的患者生存预后优于低表达者(HR=0.68, P=0.015)。miR-126-5p预测结合靶基因BRCC3 mRNA 3'UTR区, 二者表达量呈负相关(r=-0.197, P < 0.05);与正常组织相比, BRCC3在肺腺癌患者中呈现高表达, 与患者不良预后相关(HR=1.39, P < 0.05)。对照组血清中miR-126-5p高于肺腺癌患者(1.23±0.21 vs 0.63±0.12, P < 0.05)。
结论: 肺腺癌组织中miR-126-5p表达水平低于正常肺组织, 肺腺癌患者外周血清中miR-126-5p表达水平低于正常人, miR-126-5p高表达患者预后较好, 低表达患者预后较差。通过生物信息学预测, miR-126-5p可能通过调控BRCC3发挥抑癌作用。
Keywords: microRNA; non-small cell lung cancer; prognosis.